Figure 2From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomesRelationship between duration of PEGV therapy and final daily dose according to outcome. Correlation between duration of PEGV therapy (months) and final daily PEGV dose (mg/day) in all patients (both groups) with IGF-I normalization at the end of follow-up (A, upper panel, ◊) and all patients (both groups) with non-normalized IGF-I levels at the end of follow-up (B, lower panel, Δ). Regression coefficient (r) and p value are shown.Back to article page